2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bidirectional gut-brain-microbiota axis as a potential link between inflammatory bowel disease and ischemic stroke

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Emerging evidence suggests that gut-brain-microbiota axis (GBMAx) may play a pivotal role linking gastrointestinal and neuronal disease. In this review, we summarize the latest advances in studies of GBMAx in inflammatory bowel disease (IBD) and ischemic stroke. A more thorough understanding of the GBMAx could advance our knowledge about the pathophysiology of IBD and ischemic stroke and help to identify novel therapeutic targets via modulation of the GBMAx.

          Related collections

          Most cited references 64

          • Record: found
          • Abstract: found
          • Article: not found

          Brain-gut interactions in inflammatory bowel disease.

          Psycho-neuro-endocrine-immune modulation through the brain-gut axis likely has a key role in the pathogenesis of inflammatory bowel disease (IBD). The brain-gut axis involves interactions among the neural components, including (1) the autonomic nervous system, (2) the central nervous system, (3) the stress system (hypothalamic-pituitary-adrenal axis), (4) the (gastrointestinal) corticotropin-releasing factor system, and (5) the intestinal response (including the intestinal barrier, the luminal microbiota, and the intestinal immune response). Animal models suggest that the cholinergic anti-inflammatory pathway through an anti-tumor necrosis factor effect of the efferent vagus nerve could be a therapeutic target in IBD through a pharmacologic, nutritional, or neurostimulation approach. In addition, the psychophysiological vulnerability of patients with IBD, secondary to the potential presence of any mood disorders, distress, increased perceived stress, or maladaptive coping strategies, underscores the psychological needs of patients with IBD. Clinicians need to address these issues with patients because there is emerging evidence that stress or other negative psychological attributes may have an effect on the disease course. Future research may include exploration of markers of brain-gut interactions, including serum/salivary cortisol (as a marker of the hypothalamic-pituitary-adrenal axis), heart rate variability (as a marker of the sympathovagal balance), or brain imaging studies. The widespread use and potential impact of complementary and alternative medicine and the positive response to placebo (in clinical trials) is further evidence that exploring other psycho-interventions may be important therapeutic adjuncts to the conventional therapeutic approach in IBD. Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immunopathology of inflammatory bowel disease.

            Inflammatory bowel disease (IBD) results from a complex series of interactions between susceptibility genes, the environment, and the immune system. The host microbiome, as well as viruses and fungi, play important roles in the development of IBD either by causing inflammation directly or indirectly through an altered immune system. New technologies have allowed researchers to be able to quantify the various components of the microbiome, which will allow for future developments in the etiology of IBD. Various components of the mucosal immune system are implicated in the pathogenesis of IBD and include intestinal epithelial cells, innate lymphoid cells, cells of the innate (macrophages/monocytes, neutrophils, and dendritic cells) and adaptive (T-cells and B-cells) immune system, and their secreted mediators (cytokines and chemokines). Either a mucosal susceptibility or defect in sampling of gut luminal antigen, possibly through the process of autophagy, leads to activation of innate immune response that may be mediated by enhanced toll-like receptor activity. The antigen presenting cells then mediate the differentiation of naïve T-cells into effector T helper (Th) cells, including Th1, Th2, and Th17, which alter gut homeostasis and lead to IBD. In this review, the effects of these components in the immunopathogenesis of IBD will be discussed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease

               Tao Zuo,  Siew C. Ng (2018)
              In the twenty first century, the changing epidemiology of inflammatory bowel disease (IBD) globally with increasing disease incidence across many countries relates to the altered gut microbiota, due to a combinatorial effect of environmental factors, human immune responses and genetics. IBD is a gastrointestinal disease associated with a gut microbial dysbiosis, including an expansion of facultative anaerobic bacteria of the family Enterobacteriaceae. Advances in high-throughput sequencing enable us to entangle the gut microbiota in human health and IBD beyond the gut bacterial microbiota, expanding insights into the mycobiota, virobiota and helminthes. Caudovirales (viruses) and Basidiomycota, Ascomycota, and Candida albicans (fungi) are revealed to be increased in IBD. The deconvolution of the gut microbiota in IBD lays the basis for unveiling the roles of these various gut microbiota components in IBD pathogenesis and being conductive to instructing on future IBD diagnosis and therapeutics. Here we comprehensively elucidate the alterations in the gut microbiota in IBD, discuss the effect of diets in the gut microbiota in relation to IBD, and illustrate the potential of manipulation of gut microbiota for IBD therapeutics. The therapeutic strategy of antibiotics, prebiotics, probiotics and fecal microbiota transplantation will benefit the effective application of precision microbiome manipulation in IBD.
                Bookmark

                Author and article information

                Contributors
                airmanzhao2016@163.com
                xiongqiutang@whu.edu.cn
                cstary@stanford.edu
                omer.k.mahgoub@whu.edu.cn
                yeyingze@whu.edu.cn
                gulijuan@whu.edu.cn
                xiaoxingxiong@whu.edu.cn
                smzhu20088@zju.edu.cn
                Journal
                J Neuroinflammation
                J Neuroinflammation
                Journal of Neuroinflammation
                BioMed Central (London )
                1742-2094
                11 December 2018
                11 December 2018
                2018
                : 15
                Affiliations
                [1 ]ISNI 0000 0004 1758 2270, GRID grid.412632.0, Department of Gastroenterology, , Renmin Hospital of Wuhan University, ; Wuhan, China
                [2 ]ISNI 0000 0004 1758 2270, GRID grid.412632.0, Diabetes Research Center, , Renmin Hospital of Wuhan University, ; Wuhan, China
                [3 ]ISNI 0000000419368956, GRID grid.168010.e, Department of Anesthesiology, Perioperative and Pain Medicine, , Stanford University School of Medicine, ; Stanford, CA 94305 USA
                [4 ]ISNI 0000 0004 1758 2270, GRID grid.412632.0, Central Laboratory, , Renmin Hospital of Wuhan University, ; Wuhan, China
                [5 ]ISNI 0000 0004 1759 700X, GRID grid.13402.34, Department of Anesthesiology, The First Affiliated Hospital, College of Medicine, , Zhejiang University, ; Hangzhou, 310000 Zhejiang China
                [6 ]ISNI 0000 0004 1758 2270, GRID grid.412632.0, Department of Neurosurgery, , Renmin Hospital of Wuhan University, ; 99 Zhang Zhidong Rd, Wuhan, 430060 Hubei China
                Article
                1382
                10.1186/s12974-018-1382-3
                6290529
                30537997
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 81571147, 81870939
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000968, American Heart Association;
                Award ID: 14FTF19970029
                Award Recipient :
                Categories
                Review
                Custom metadata
                © The Author(s) 2018

                Comments

                Comment on this article